Globus Medical, Inc. $GMED is Global Alpha Capital Management Ltd.’s 4th Largest Position

Global Alpha Capital Management Ltd. reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 41.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 666,696 shares of the medical device company’s stock after selling 478,895 shares during the quarter. Globus Medical comprises 3.6% of Global Alpha Capital Management Ltd.’s portfolio, making the stock its 4th biggest holding. Global Alpha Capital Management Ltd.’s holdings in Globus Medical were worth $58,209,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. grew its position in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Globus Medical by 2.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock worth $375,000 after buying an additional 170 shares during the period. Parallel Advisors LLC grew its position in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the period. EverSource Wealth Advisors LLC grew its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares during the period. Finally, Allworth Financial LP grew its position in Globus Medical by 1.6% during the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock worth $1,095,000 after buying an additional 199 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GMED has been the topic of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Needham & Company LLC lifted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Truist Financial set a $115.00 target price on shares of Globus Medical in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $106.36.

Globus Medical Stock Performance

GMED stock opened at $80.13 on Friday. The stock has a market capitalization of $10.88 billion, a P/E ratio of 18.63, a PEG ratio of 1.65 and a beta of 0.95. The company has a 50 day moving average price of $86.27 and a two-hundred day moving average price of $88.21. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter last year, the business earned $0.68 EPS. Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.